Pluri Secures China Patent for Large-Scale Immune Cell Manufacturing Platform
Key Insights
Pluri Inc. (search) received a patent from China's National Intellectual Property Administration for its proprietary 3D immune cell expansion and activation technology, expanding its global IP portfolio across major pharmaceutical markets.
The patent covers large-scale production of diverse immune cell types including CAR-T, NK cells, and MAIT cells using an automated bioreactor system that mimics the human lymph node environment.
The company now holds patent protection across the U.S., China, Japan, Korea, Australia and Israel, creating an "IP Bridge" for global pharmaceutical partnerships in cell therapy development.
Pluri Inc. (search) has secured a strategic patent from the China National Intellectual Property Administration (search) (CNIPA) for its proprietary 3D immune cell expansion and activation technology, significantly strengthening the biotechnology company's global intellectual property position in the rapidly growing cell therapy market.
The patent, titled "System and Methods for Immune Cells Expansion and Activation in Large Scale" (Patent No. Cn 119301238 b), covers Pluri's automated manufacturing platform for large-scale production of diverse immune cell types, both unmodified and genetically modified. The technology enables expansion of cell types spanning lymphoid and myeloid lineages, including conventional and unconventional T cells such as MAIT cells, Natural Killer (NK) cells, Tumor Infiltrating Lymphocytes (TIL), and Chimeric Antigen Receptor (CAR) and T Cell Receptor (TCR) engineered variants.
Global IP Portfolio Expansion
With this China patent grant, Pluri now holds patent protection across the U.S., China, Japan, Korea, Australia and Israel, creating what the company describes as an "IP Bridge" for partners developing therapies across the world's primary healthcare markets. This broad coverage supports a unified framework for international licensing and development, helping global pharmaceutical companies operate in China with greater confidence while enabling Chinese biotech leaders to pursue global expansion.
"We believe that securing patent protection in China, one of the most dynamic cell therapy markets globally, validates the novelty and scalability of our technology," said Yaky Yanay, Chief Executive Officer and President of Pluri. "Together with our granted patents in the U.S., Japan, Korea, Australia and Israel, our goal is to offer partners a globally protected manufacturing platform capable of supporting large-scale immune cell production."
Addressing Manufacturing Bottlenecks
Pluri's patented 3D platform addresses industry bottlenecks through a unique bioreactor system that mimics the human lymph node environment to expand billions of immune cells. The company believes this approach significantly enhances cost-efficiency by reducing the prohibitive expenses typically associated with traditional cell therapy production, a critical requirement for the high-volume Chinese pharmaceutical market.
The platform ensures rigorous quality control through a fully automated, closed-loop process that maintains batch-to-batch consistency and cell integrity at an industrial scale. By protecting key manufacturing methods in both CNIPA and U.S. Patent and Trademark Office jurisdictions, Pluri's cross-continental defensibility can potentially reduce partnering risk and strengthen high-value collaborations where scalability, quality consistency and IP protection are critical to commercial success.
Strategic Market Positioning
The patent grant comes at a pivotal moment for China's rapidly expanding cell therapy landscape. China has emerged as one of the world's most dynamic markets for CAR-T and advanced cell therapies, driven by growing clinical adoption, expanding manufacturing infrastructure, and increased investment. Protecting Pluri's IP in China not only strengthens the company's global portfolio but strategically positions it to participate and contribute to one of the fastest-growing ecosystems worldwide.
Pluri is a biotechnology company pioneering mass-scale cell expansion and biofarming using its patented, proprietary 3D cell expansion platform. The company develops scalable, consistent, and cost-efficient cell-based solutions, driving innovation in regenerative medicine, foodtech, agtech, aesthetics and offering Contract Development and Manufacturing Organization (CDMO) services. With two decades of experience and a strong intellectual property portfolio, Pluri accelerates breakthroughs that address global challenges in healthcare and other sectors.